奥曲肽在小细胞肺癌合并低钠血症患者中的临床应用观察  

Application of Octreotide in the Treatment of Patients with Small Cell Lung Cancer Combined with Hyponatremia

作　　者：郑俊琼[1] 陈志勇[1] 廖雪燕[1] 

机构地区：[1]福建医科大学附属龙岩市第一医院肿瘤内科,福建龙岩364000

出　　处：《肿瘤基础与临床》2015年第6期529-531,共3页journal of basic and clinical oncology

摘　　要：目的观察奥曲肽在小细胞肺癌合并低钠血症患者中对低钠血症的治疗疗效和安全性。方法 60例小细胞肺癌合并低钠血症患者分为2组,奥曲肽组24例采用奥曲肽联合化疗、补钠支持治疗,对照组36例采用化疗、补钠支持治疗,观察低钠血症纠正时间、参加化疗率、生活质量改善情况以及毒副反应。结果奥曲肽组低钠血症纠正时间为(4.86±1.76)d,对照组为(14.43±3.68)d,差异有统计学意义(P<0.05)。奥曲肽组参加化疗率为100.0%,高于对照组的83.3%,差异有统计学意义(P<0.05)。2组生活质量改善情况比较差异有统计学意义(P<0.05)。2组毒副反应发生情况比较差异无统计学意义(P>0.05)。结论奥曲肽联合化疗、补钠支持治疗可迅速纠正小细胞肺癌合并低钠血症患者的低钠血症情况,改善患者生活质量,有利于化疗的尽早进行。Objective To observe the efficacy and safety of octreotide in the treatment of patients with small cell lung cancer combined with hyponatremia. Methods Sixty patients with small cell lung combined with hyponatremia were divided into two groups,24 patients of the octreotide group received octreotide,chemotherapy and sodium treatment, and 36 patients of the control group received chemotherapy and sodium treatment,the corrected blood sodium time, the chemotherapy rate,quality of life and toxicities were evaluated. Results The corrected blood sodium time of the octreotide group was shorter than that of the control group [ （4.86 ± 1.76） days vs （ 14.43 ±3.68 ） days, P 〈 0.05 ]. The chemotherapy rate of the octreotide group was higher than that of the control group（ 100.0% vs 83.3%, P 〈 0.05 ）. The quality of life of the octreotide group was better than that of the control group （P 〈 0.05 ）. There was no statistical difference in the toxicities between the two groups （P 〈 0.05 ）. Conclusion The octreotide, chemotherapy and sodium treatment could correct the blood sodium of patients with small cell lung cancer combined with hyponatremia, and improve the quality of life, and promote the smooth progress of chemotherapy.

关 键 词：奥曲肽 小细胞肺癌 低钠血症 

分 类 号：R734.2[医药卫生—肿瘤] R591.1[医药卫生—临床医学]